These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35456627)

  • 1. Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies.
    Lederer CW; Koniali L; Buerki-Thurnherr T; Papasavva PL; La Grutta S; Licari A; Staud F; Bonifazi D; Kleanthous M
    Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
    Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
    Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
    Kočí Z; Boráň T; Krůpa P; Kubinová Š
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
    Beattie S;
    Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease.
    Woods N; MacLoughlin R
    Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32993197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced therapy medicinal products in China: Regulation and development.
    Lu J; Xu L; Wei W; He W
    MedComm (2020); 2023 Jun; 4(3):e251. PubMed ID: 37125239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced therapy medicinal products: current and future perspectives.
    Hanna E; Rémuzat C; Auquier P; Toumi M
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework.
    López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pipeline analysis of advanced therapy medicinal products.
    Wilkins GC; Lanyi K; Inskip A; Ogunbayo OJ; Brhlikova P; Craig D
    Drug Discov Today; 2023 May; 28(5):103549. PubMed ID: 36963609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European regulatory tools for advanced therapy medicinal products.
    Flory E; Reinhardt J
    Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine.
    Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A
    J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
    Ancans J
    Front Immunol; 2012; 3():253. PubMed ID: 22912639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of Mesenchymal Stem Cell Therapy as an Advanced Therapeutic Medicinal Product (ATMP)-An Indian Perspective.
    Muthu S; Jeyaraman M; Kotner MB; Jeyaraman N; Rajendran RL; Sharma S; Khanna M; Rajendran SNS; Oh JM; Gangadaran P; Ahn BC
    Bioengineering (Basel); 2022 Mar; 9(3):. PubMed ID: 35324800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
    Bakopoulou A
    J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Therapy Medicinal Products and Exemptions to the Regulation 1394/2007: How Confident Can We be? An Exploratory Analysis.
    Van Wilder P
    Front Pharmacol; 2012; 3():12. PubMed ID: 22347860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene and cell therapy for children--new medicines, new challenges?
    Buckland KF; Bobby Gaspar H
    Adv Drug Deliv Rev; 2014 Jun; 73(100):162-9. PubMed ID: 24583376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective.
    Pizevska M; Kaeda J; Fritsche E; Elazaly H; Reinke P; Amini L
    Front Med (Lausanne); 2022; 9():757647. PubMed ID: 35186986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe.
    Ten Ham RMT; Hoekman J; Hövels AM; Broekmans AW; Leufkens HGM; Klungel OH
    Mol Ther Methods Clin Dev; 2018 Dec; 11():121-130. PubMed ID: 30456217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.